wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q38916996-FDEEEFA8-E4B6-42EE-B7B5-653317C1D3A8
Q38916996-FDEEEFA8-E4B6-42EE-B7B5-653317C1D3A8
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38916996-FDEEEFA8-E4B6-42EE-B7B5-653317C1D3A8
Response assessment in metronomic chemotherapy: RECIST or PERCIST?
P2860
Q38916996-FDEEEFA8-E4B6-42EE-B7B5-653317C1D3A8
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38916996-FDEEEFA8-E4B6-42EE-B7B5-653317C1D3A8
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
40f1791e9278aa0a432dbde8d3ede90467aa1732
P2860
Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors.